Chordoma Clinical Trial
Official title:
Phase II Evaluation of Proton Beam Therapy for Skull Base Chordoma
The goal of this clinical research study is to learn if proton beam therapy, with or without photon beam radiation therapy, is effective in the treatment of skull base chordoma. The safety of this treatment will also be studied.
Proton therapy is a kind of external beam radiation therapy where protons are directed to a tumor site. Researchers are trying to determine what level of proton therapy gives the most benefit without causing toxic side effects. Researchers will also be testing the treatment's effect. If your doctor feels it is necessary, the proton beam therapy may be combined with standard photon therapy. If you are eligible to take part in this study, you will receive proton beam therapy at The University of Texas (UT) MD Anderson Cancer Center (MDACC), and possibly photon beam, no sooner than 2 weeks after the last surgery to remove the tumor. You will receive proton beam therapy once a day for about 35 treatments (7 weeks). Treatment will be given for 5 days in a row each week (except for Saturdays, Sundays and holidays) at the MDACC Proton Center in Houston. The whole process should take up to 1 hour each day. This is an investigational study. The proton beam machine used to deliver treatment is approved by the FDA for patient use. The doses being studied are experimental. About 15 participants will take part in this study. All will be enrolled at MDACC. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03955042 -
Pemetrexed for the Treatment of Chordoma
|
Phase 1 | |
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
Completed |
NCT03595228 -
BN Brachyury and Radiation in Chordoma
|
Phase 2 | |
Recruiting |
NCT06140732 -
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
|
Phase 2 | |
Active, not recruiting |
NCT01175109 -
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
|
Phase 1 | |
Completed |
NCT00150072 -
Efficacy and Safety of Imatinib in Chordoma
|
Phase 2 | |
Terminated |
NCT00003926 -
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05041127 -
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
|
Phase 2 | |
Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT02383498 -
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
|
Phase 2 | |
Recruiting |
NCT03242382 -
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
|
Phase 2 | |
Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
Recruiting |
NCT02986516 -
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
|
N/A | |
Completed |
NCT00919269 -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
|
||
Active, not recruiting |
NCT02989636 -
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
|
Phase 1 | |
Active, not recruiting |
NCT03083678 -
Afatinib in Locally Advanced and Metastatic Chordoma
|
Phase 2 | |
Completed |
NCT00713037 -
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
|
N/A |